Stockscreener 앱 받기
2.97
1.66%
-0.05
시간 외 거래:
2.97
전일 마감가:
$3.02
열려 있는:
$2.97
하루 거래량:
468.92K
Relative Volume:
1.00
시가총액:
$71.44M
수익:
$66.58M
순이익/손실:
$-19.95M
주가수익비율:
-3.229
EPS:
-0.9198
순현금흐름:
$-14.27M
1주 성능:
-6.01%
1개월 성능:
-9.17%
6개월 성능:
-68.93%
1년 성능:
-20.80%
1일 변동 폭
$2.88
$3.06
1주일 범위
$2.88
$3.29
52주 변동 폭
$2.88
$12.23
Exagen Inc Stock (XGN) Company Profile
명칭
Exagen Inc
전화
(760) 560-1501
주소
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
2.97 | 72.64M | 66.58M | -19.95M | -14.27M | -0.9198 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-11 | 개시 | B. Riley Securities | Buy |
| 2025-07-30 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | 개시 | Craig Hallum | Buy |
| 2022-08-05 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-04-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | 개시 | BTIG Research | Buy |
| 2020-06-02 | 재개 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-10-14 | 개시 | Cowen | Outperform |
| 2019-10-14 | 개시 | William Blair | Outperform |
모두보기
Exagen Inc 주식(XGN)의 최신 뉴스
Exagen (XGN) director lists 7,500 restricted stock units in Form 3 - Stock Titan
Exagen (XGN) CFO receives option, RSU grants and ESPP share purchase - Stock Titan
Exagen (XGN) CEO John Aballi awarded new RSUs and options - Stock Titan
Exagen prices public offering of common stock - MSN
Exagen Inc. (NASDAQ:XGN) Short Interest Update - MarketBeat
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat - AD HOC NEWS
Exagen Inc Stock (ISIN: US30063K1051) Faces Headwinds After 2025 Revenue Beat and Cautious 2026 Outl - AD HOC NEWS
Exagen (NASDAQ:XGN) Downgraded by Wall Street Zen to Sell - MarketBeat
Exagen stock price target lowered to $10 by Canaccord on margin outlook - Investing.com UK
KeyBanc cuts Exagen stock price target on pricing headwinds - Investing.com Nigeria
Exagen (XGN): Canaccord Genuity Lowers Price Target to $10.00 | - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Annual Report: Innovative AVISE® Autoimmune Disease Testing, Business Strategy, Pipeline, and Intellectual Property Overview - Minichart
Analyst John Wilkin Lowers Price Target for Exagen (XGN) | XGN S - GuruFocus
Exagen (NASDAQ:XGN) Price Target Cut to $10.00 by Analysts at Craig Hallum - MarketBeat
KeyBanc cuts Exagen stock price target on pricing headwinds By Investing.com - Investing.com Canada
XGN: Keybanc Lowers Price Target to $10, Maintains Overweight Ra - GuruFocus
KeyCorp Issues Pessimistic Forecast for Exagen (NASDAQ:XGN) Stock Price - MarketBeat
Exagen Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-03-11 - Seeking Alpha
Exagen stock price target lowered to $10 by Canaccord on margin outlook By Investing.com - Investing.com Canada
Exagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadence - MSN
BTIG cuts Exagen stock price target to $9 on lower revenue outlook By Investing.com - Investing.com India
William Blair Maintains Outperform on Exagen Inc. (XGN) March 2026 - Meyka
BTIG cuts Exagen stock price target to $9 on lower revenue outlook - Investing.com India
Exagen (XGN) Rating Maintained by BTIG, Price Target Lowered to $9.00 | XGN Stock News - GuruFocus
Exagen (NASDAQ:XGN) Price Target Lowered to $9.00 at BTIG Research - MarketBeat
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Exagen Inc (XGN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Investments - GuruFocus
4 Analysts Have This To Say About Exagen - Benzinga
Exagen stock maintains Outperform rating at William Blair By Investing.com - Investing.com India
Exagen stock maintains Outperform rating at William Blair - Investing.com Australia
Exagen Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations - Investing.com India
Exagen Inc. Reports Strong Q4 and Full-Year 2025 Financial Results – Earnings Press Release March 2026 - Minichart
Exagen Q4 Earnings Call Highlights - MarketBeat
Exagen (XGN) Achieves Record Q4 Revenue, Driven by Test Volume G - GuruFocus
XGN Forecasts Significant Revenue Growth by 2026 - GuruFocus
Exagen Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Earnings call transcript: Exagen Inc. misses Q4 2025 earnings expectations By Investing.com - Investing.com South Africa
Exagen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Exagen 2025 10-K: Revenue $66.6M; net loss $(19.95)M - TradingView
XGN: Record 2025 revenue of $66.6M (+19.7%) with net loss of $20.0M; strong AVISE® CTD growth - TradingView
Exagen Inc. (NASDAQ:XGN) Reports Record 2025 Revenue and Provides 2026 Outlook - ChartMill
Exagen Inc. (XGN) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Exagen (NASDAQ:XGN) Releases Quarterly Earnings Results, Hits Estimates - MarketBeat
EXAGEN DIAGNOSTICS ($XGN) Releases Q4 2025 Earnings - Quiver Quantitative
Exagen reports record 2025 revenue $66.6M, ASP rises to $441; Q4 revenue $16.6M - TradingView
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results - The Manila Times
Exagen Earnings Report: Q4 Overview - Benzinga
BRIEF-Exagen Inc. Q4 Revenue USD 16.631 Million Vs. IBES Estimate USD 16.6 Million - TradingView
Autoimmune tests for over 137,000 patients power Exagen's 20% revenue rise - Stock Titan
Exagen Inc (XGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):